An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Nebilet Administered in Korean Patients According to the Prescribing Information
Overview
- Phase
- Not Applicable
- Intervention
- Nebivolol
- Conditions
- Hypertension
- Sponsor
- GlaxoSmithKline
- Enrollment
- 743
- Locations
- 1
- Primary Endpoint
- Occurrence of adverse events after Nebivolol administration
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Nebivolol administered in Korean patients according to the prescribing information
Detailed Description
An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Nebivolol administered in Korean patients according to the prescribing information Nebivolol will be administered to Hypertension or Chronic heart failure (CHF) patients as described the prescribing information of Nebivolol by physician's decision.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Patients administrated Nebivolol
There is only one group. This group includes patients administrated Nebivolol
Intervention: Nebivolol
Outcomes
Primary Outcomes
Occurrence of adverse events after Nebivolol administration
Time Frame: 3months, 6months
Secondary Outcomes
- Occurrence of unexpected or serious adverse event after Nebivolol administration and effectiveness of Occurrence of unexpected or serious adverse event after Nebivolol administration and effectiveness of Nebivolol(3 months, 6months)